Impact of ERAS Protocol on Length of Hospital Stay After Laparoscopic Surgeries

NCT ID: NCT07116564

Last Updated: 2025-08-11

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

PHASE4

Total Enrollment

98 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-08-01

Study Completion Date

2026-11-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this clinical trial is to determine the length of hospital stay in patients using multimodal analgesia with or without ERAS protocol scheduled for elective laparoscopic gynecological surgeries

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

ERAS

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group C

Group Type ACTIVE_COMPARATOR

Control

Intervention Type DRUG

Preoperatively, NPO 6 hours before the procedure Intraoperatively, on induction Nabuphine 0.1mg/kg

Group E

Group Type EXPERIMENTAL

Enhanced Recovery After Surgery

Intervention Type DRUG

Preoperatively ERAS protocol includes, No solid food for 6 hours before procedure; 800 ml (fantomalt powder) Carbohydrate drink 8 hours before surgery; 400 ml (fantomalt powder) 2 hours before surgery; Celecoxib 200g 1 hour before surgery . Intraoperatively, on induction lidocaine 1.5 mg/kg and Fentanyl 1 to 2 mcg/kg followed by IV lidocaine infusion at 1.5 mg/kg/h.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Enhanced Recovery After Surgery

Preoperatively ERAS protocol includes, No solid food for 6 hours before procedure; 800 ml (fantomalt powder) Carbohydrate drink 8 hours before surgery; 400 ml (fantomalt powder) 2 hours before surgery; Celecoxib 200g 1 hour before surgery . Intraoperatively, on induction lidocaine 1.5 mg/kg and Fentanyl 1 to 2 mcg/kg followed by IV lidocaine infusion at 1.5 mg/kg/h.

Intervention Type DRUG

Control

Preoperatively, NPO 6 hours before the procedure Intraoperatively, on induction Nabuphine 0.1mg/kg

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* ASA physical status I, II, and III
* Patients scheduled for elective laparoscopic gynecological surgeries

Exclusion Criteria

* Refusal to participate
* History of allergy or contraindication to study drugs
* Patients in which procedure converted to open surgery
* Diagnostic laparoscopic procedures
* Patients with a history of severe anxiety or depression
Minimum Eligible Age

20 Years

Maximum Eligible Age

60 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Aga Khan University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Ali Sarfraz Siddiqui

Assistant Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Ali Sarfraz Siddiqui, MBBS, MCPS, FCPS, FIPP, MHPE

Role: CONTACT

+922134864397 ext. 4397

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2025-11268-35403

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.